Compare · GRAY vs LLY
GRAY vs LLY
Side-by-side comparison of Graybug Vision Inc. (GRAY) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GRAY and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.06T, about 39002.6x GRAY ($27.1M).
- LLY has hit the wire 13 times in the past 4 weeks while GRAY has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 0 for GRAY).
- Company
- Graybug Vision Inc.
- Eli Lilly and Company
- Price
- $5.65+1016.16%
- $1121.18-2.41%
- Market cap
- $27.1M
- $1.06T
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 13
- Recent ratings
- 0
- 25
Graybug Vision Inc.
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest GRAY
- Amendment: SEC Form S-1/A filed by Graybug Vision Inc.
- Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors
- Graybug Vision Inc. filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form EFFECT filed by Graybug Vision Inc.
- SEC Form SC 13D/A filed by Graybug Vision Inc. (Amendment)
- SEC Form SC 13G/A filed by Graybug Vision Inc. (Amendment)
- SEC Form SC 13G/A filed by Graybug Vision Inc. (Amendment)
- Roberts Eric W was granted 91,086 shares, increasing direct ownership by 449% to 111,373 units (SEC Form 4)
- SEC Form SC 13D/A filed by Graybug Vision Inc. (Amendment)
- SEC Form SC 13G filed by Graybug Vision Inc.
Latest LLY
- EVP, Global Quality Seymour Melissa converted options into 981 shares and covered exercise/tax liability with 439 shares, increasing direct ownership by 103% to 1,067 units (SEC Form 4)
- Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
- New insider Eli Lilly & Co claimed ownership of 1,054,828 shares (SEC Form 3)
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
- Lilly confirms date and conference call for second-quarter 2026 financial results announcement
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,000 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,905 units (SEC Form 4)
- Director Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,410 units (SEC Form 4)
- Director Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,734 units (SEC Form 4)
- Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates